FY2017 EPS Estimates for ProMetic Life Sciences Inc. Lifted by Hybridan Llp (PLI)

ProMetic Life Sciences Inc. (TSE:PLI) – Equities research analysts at Hybridan Llp lifted their FY2017 earnings per share (EPS) estimates for ProMetic Life Sciences in a note issued to investors on Thursday. Hybridan Llp analyst D. Nathan now forecasts that the company will post earnings per share of ($0.16) for the year, up from their previous forecast of ($0.18). Hybridan Llp also issued estimates for ProMetic Life Sciences’ FY2018 earnings at ($0.03) EPS.

WARNING: This article was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/11/20/fy2017-eps-estimates-for-prometic-life-sciences-inc-lifted-by-hybridan-llp-pli.html.

PLI has been the topic of a number of other reports. National Bank Financial cut their price objective on ProMetic Life Sciences from C$2.50 to C$2.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 15th. Royal Bank Of Canada cut their price objective on ProMetic Life Sciences from C$4.00 to C$3.50 and set an “outperform” rating on the stock in a research note on Wednesday, August 16th. Finally, TD Securities dropped their price target on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating on the stock in a research report on Wednesday, August 16th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of C$3.50.

ProMetic Life Sciences (TSE PLI) opened at C$1.41 on Monday. ProMetic Life Sciences has a one year low of C$1.12 and a one year high of C$2.88.

In other news, Director Dwun-Hou Chen sold 32,321 shares of ProMetic Life Sciences stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of C$1.14, for a total transaction of C$36,845.94. Also, insider Bruce Pritchard acquired 48,400 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The shares were purchased at an average cost of C$1.30 per share, for a total transaction of C$62,920.00. Over the last ninety days, insiders acquired 151,300 shares of company stock worth $192,261 and sold 388,397 shares worth $507,577.

ProMetic Life Sciences Company Profile

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Earnings History and Estimates for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply